-
-
-
-
-
-
-
BeOne Medicines (ONC) PT Raised to $436 at RBC Capital
-
-
-
-
-
-
-
Jefferies Downgrades BeOne Medicines (ONC) to Hold
-
-
-
-
-
-
-
BeOne Medicines (ONC) BeOne Medicines presents oncology pipeline at JPMorgan conference
-
-
-
-
-
-
-
BeOne (ONC) Stock a Unique Buying Opportunity - Citizens
-
-
-
-
-
-
-
BeOne Medicines gets FDA breakthrough therapy status for cancer drug
-
-
-
-
-
-
-
BeOne Medicines sells IMDELLTRA royalty rights for up to $950 million
-
-
-
-
-
-
-
BeOne Medicines receives positive EU opinion for TEVIMBRA lung cancer use
-
434,554 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

